Navigation Links
After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
Date:6/9/2008

Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved Glucose

Control in Patients Switching from Exenatide Taken Twice a Day

SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY), and Alkermes, Inc. (Nasdaq: ALKS) today announced results from a 52-week open-label clinical study that showed the durable efficacy of exenatide once weekly, a long-acting release formulation of exenatide. Patients taking exenatide once weekly over the course of one year sustained a similar improvement in glucose control [A1C: -2.0%+/-0.08; fasting plasma glucose (FPG) -47+/-3 mg/dL] compared to those receiving treatment for 30 weeks [A1C change from baseline: -1.9%+/-0.08 (LS mean+/-SE)]. This study also showed that patients who switched from BYETTA(R) (exenatide) injection after 30 weeks to exenatide once weekly experienced additional improvements in A1C and fasting plasma glucose. Seventy-four percent of all patients in the study achieved an endpoint A1C of 7 percent or less at 52 weeks. Patients in both treatment groups experienced a statistically significant and sustained average weight loss of 9.5 pounds over 52 weeks. These findings were presented at the 68th Annual Scientific Sessions of the American Diabetes Associa
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
2. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
3. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
4. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
5. Is PCI Safe, Effective After Clot-Busters for Heart Attack?
6. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
7. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
8. Helping Families Cope After an Injury
9. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
10. AHF Seeks White House Clarification After Press Room Flap Over CDCs HIV Numbers
11. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)... , MONTVALE, N.J., Nov. 19 /PRNewswire-First...EMY ) today announced that it has achieved the enr...54, its lead alpha-7 nicotinic receptor agonist, i...ia (CIAS). The Company has randomized 212 patient...payment from its partner Roche. Memory Pharmaceut...
(Date:11/18/2008)...gton Medical Resources (AMR), a,provider of premi...diagnostic,imaging industries, finds that over $1...he U.S. during the third quarter of 2008. Privigen...in (IVIG) and was launched in the first,quarter o...lasma of thousands,of donors and is used to treat...
(Date:11/18/2008)...d, elderly AML patients , , PRINCETON, N.J....today announced that the first patient has been tr...X-351 (Cytarabine:Daunorubicin) Liposome Injection...ukemia (AML). , , The first patient was enr...llege of Cornell University and New York Presbyte...
(Date:11/13/2008)...ut Risk of Heart Attacks, Deaths, RESTON, Va., No...sease,is the leading cause of death among American...ons of dollars and causing untold suffering. Now,t... - even among those who,weren,t thought to be at r...le could cut their risk of a,heart attack, stroke ...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Seniors Can Be Heartened by New Study on Statins 2Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock 28R 29 Set Saver 10113 1Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock 28R 29 Set Saver 10113 2Baxa Corporation Launches Campaign to Recognize IV Nurse Day and Introduce the New PadLock 28R 29 Set Saver 10113 3DuPont Chief Science 26 Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2739 1DuPont Chief Science 26 Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2739 2DuPont Chief Science 26 Technology Officer Offers Perspectives on Science and Global Policymaking at Davos World Economic Forum 2739 3Oral Contraceptives Cut Ovarian Cancer Risk 10111 1Oral Contraceptives Cut Ovarian Cancer Risk 10111 2Oral Contraceptives Cut Ovarian Cancer Risk 10111 3Report 3A Too Few Physicians Nurses to Implement Presidential Candidates Health Reform Plans 10109 1Report 3A Too Few Physicians Nurses to Implement Presidential Candidates Health Reform Plans 10109 2Report 3A Too Few Physicians Nurses to Implement Presidential Candidates Health Reform Plans 10109 3
..., Tenn.--(BUSINESS WIRE)--May 25, 2007 - GTx, Inc....e recent Phase II proof of,concept clinical trial ...nical trial evaluating ACAPODENE(R) (toremifene ci...fects of androgen,deprivation therapy (ADT) will b... the American Society of Clinical Oncology being,h...
...RSBURG, Md., May 24, 2007 /PRNewswire-FirstCall/ -...nnounce results from the,Phase 1 trial of its patc...arkets open tomorrow. A conference call and live,w...rrow to discuss,the results. , Conference Call Det...May 25, 2007 at 8:30,a.m. Eastern Time via phone, ...
Other Medicine Technology:GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3Iomai to Announce Results From Phase 1 Influenza Trial and Host,Webcast Tomorrow 2
(Date:11/21/2008)... work together to stop abusive behavior, experts s...-- Behavior that was once dismissed as "kids being...mounting research shows the negative effects on bo...ionals, schools, parents and even kids themselves ...ning behavior. , "Bullying shouldn,t be consid...
(Date:11/21/2008)...ire-FirstCall/ -- Heska Corporation,(Nasdaq: HS...rk Society of,Security Analysts, 12th Annual Biot..., 2008 at 1177 Avenue of the Americas, 2nd Floor i...begin at 9:35 a.m. Eastern Time (7:35 a.m.,Mounta...d for two weeks,following the presentation throug...
(Date:11/21/2008)...ovel technique to combat cancer, study says, ,...lgian researchers have discovered that some cancer...and this might lead to new treatments that starve ...ate, all cells in the body need to produce energy....s that requires oxygen. Compared with normal cells...
(Date:11/21/2008)...re-USNewswire/ -- U.S. News & World Report and...A) ranked BlueChoice(R) HealthPlan of South Caroli...(TM), published in U.S. News & World Report,s ...anking ranks the nation,s best health plans based ...accreditation scores. NCQA and U.S. News & Wor...
Breaking Medicine News(10 mins):Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2
...d environmental changes have caused drastic increa...ent 17% of the childhood cancer cases.// 77,111 c... 1997 in 15 European countries were analyzed in th... was an increase by an average of 1.1% a year in t...
... drug that is being developed for multiple scleros...ggests that the experimental drug fingolimod might...ultiple sclerosis. It was also reported in the stu...studies could show satisfactorily that the patient...
...nary problems than white men, but are only half as...s conducted on over 8,000 men has been published i...nternational, states that South Asian men suffer f...than white men, but are less likely to seek help. ...
...ts facing major losses to outsource medical transc...ounds a year.// Around 60 specialist posts are to ... in Leeds are reported to be facing debts of 84 mi...in Britain have already outsourced such work to In...
Other Medicine News:Health News:17 percent rise in childhood cancer cases due to modern lifestyles 2Health News:An Experimental New Drug Might Be Effective In Treating MS 2Health News:South Asian Men Have More Urinary Problems Than White Men 2Health News:Leeds Hospitals to Outsource Medical Transcription Work to India 2
Infant Nebulizer Kit W/Misty-Nebulizer 30/CS CE Mark Only
...ted Clinical Applications:, ,Cool Aerosol Therapy...th open system devices such as aerosol masks, face...de only limited FIO2 and limited flow. The design ...dental dilution with room air or high FIO2 due to ...
...w PARI TREK™ Compact Compressor is for activ...ts anywhere and everywhere. The compressor is smal...ower source optionsworldwide AC compatibility (100...rmit patients the freedom to take aerosol treatmen...
...ucing Quieter Compressed Air., ,Allied Healthcare...so much quieter than other air compressors that yo... too. The PCS 414 features a durable, mar-resistan..., the unit weighs only 26.5 pounds. The PCS 414 ha...
Medicine Products: